Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Golo Ahlenstiel"'
Autor:
Geoff Collins, Paul K. Witting, Yuyang Liu, Gulfam Ahmad, Andrew N. Harman, Scott N. Byrne, Mary El Kazzi, Angie L Schroder, James Wei Tatt Toh, Grahame Ctercteko, Chloe M Doyle, Golo Ahlenstiel, Nimalan Pathma-Nathan, Belal Chami
Publikováno v:
Inflammatory Bowel Diseases. 28:586-598
Background Intestinal neutrophil recruitment is a characteristic feature of the earliest stages of inflammatory bowel disease (IBD). Neutrophil elastase (NE) and myeloperoxidase (MPO) mediate the formation of neutrophil extracellular traps (NETs); NE
Autor:
Liia Akhuba, Golo Ahlenstiel, Dmitrii Shek, Bo Gao, Adnan Nagrial, Scott A. Read, Matteo S. Carlino, Tania Moujaber
Publikováno v:
Cancers
Cancers, Vol 13, Iss 4345, p 4345 (2021)
Cancers, Vol 13, Iss 4345, p 4345 (2021)
Simple Summary In 2018, colorectal cancer (CRC) was declared the fourth most deadly cancer worldwide. Unfortunately, a quarter of all patients are diagnosed at late stages, when curative surgery is not possible, rendering systemic therapy and/or best
Autor:
Bo Gao, Golo Ahlenstiel, Scott A. Read, Adnan Nagrial, Matteo S. Carlino, Dmitrii Shek, Jacob George
Publikováno v:
Oncologist
Hepatocellular carcinoma (HCC) is the fourth most common cause of cancer-related death worldwide. A first-line standard of care, sorafenib results in median overall survival of 12 months in patients with Child-Pugh class A disease and 6 months in pat
Autor:
Yaron Rotman, Elisavet Serti, Jordan J. Feld, JM Werner, Golo Ahlenstiel, T. Jake Liang, Jonathan D. Stoltzfus, Xenia Chepa-Lotrea, Mazen Noureddin, Barbara Rehermann
Publikováno v:
Hepatology. 60:1160-1169
Ribavirin (RBV) is an important component of interferon (IFN)-based and direct antiviral treatment regimens for hepatitis C virus (HCV) infection. Immunomodulation, in particular improvement of the host IFN response, has been proposed as RBV's mechan
Autor:
Vito Attino, Mark W. Douglas, Mohammed Eslam, Diane Goeltz, Jacob Nattermann, Ulrich Spengler, Abed M. Zaitoun, Manuel Romero-Gómez, David Sheridan, William L. Irving, Jacob George, Alessandra Mangia, Reynold Leung, Elisabetta Bugianesi, Lindsay Mollison, Golo Ahlenstiel, David R. Booth, Wendy Cheng, Duncan McLeod
Publikováno v:
Journal of Hepatology. 61:235-241
Background & Aims Single nucleotide polymorphisms (SNPs) near the interferon lambda 3 ( IFNL3 , previously known as IL28B ) region are the strongest baseline predictors of sustained virologic response (SVR) to pegylated interferon and ribavirin thera
Autor:
V. Suppiah, Jacob Nattermann, Elizabeth E. Powell, Antonina Smedile, M. Michalk, Mandvi Bharadwaj, Sherie Smith, Shona Fletcher, Martin Weltman, Julie R. Jonsson, Elizabeth Snape, David Sheridan, Gregory J. Dore, Patrick McClure, Richard Norris, Helen Barrie, M.L. Abate, David R. Booth, Dianne How-Chow, Thomas Berg, Jacob George, Jason Grebely, G. J. Stewart, Stephen M. Riordan, Margaret Bassendine, Sacha Stelzer-Braid, Golo Ahlenstiel, William L. Irving, Ulrich Spengler, Tobias Mueller, Nicola J. Armstrong, Vincenzo Fragomeli, Barbara Malik, Kate S. O'Connor, Tanya L. Applegate, Gail V. Matthews
Publikováno v:
BASE-Bielefeld Academic Search Engine
IL28B polymorphisms strongly predict spontaneous and treatment-induced clearance of hepatitis C virus (HCV) infection. A recent study proposed a 32-base pair deletion in the CC-chemokine receptor 5 (CCR5) gene (CCR5-D32) interacting with the IL28B po
Publikováno v:
Journal of Gastroenterology. 45:903-910
Three landmark genome-wide association studies (GWAS) published in 2009 identified the interleukin (IL) 28B gene locus as pivotal to the pathogenesis of hepatitis C virus (HCV) infection. Polymorphisms near the IL28B gene not only predicted treatment
Autor:
Vijayaprakash Suppiah, Tobias Müller, Max Moldovan, Maria Lorena Abate, Margaret F. Bassendine, David Sheridan, Martin Weltman, Ulrich Spengler, Jacob George, Melanie Bahlo, Thomas Berg, Vincenzo Fragomeli, Gregory J. Dore, Antonina Smedile, Elizabeth E. Powell, Stephen M. Riordan, Graeme J. Stewart, David R. Booth, Golo Ahlenstiel
Publikováno v:
BASE-Bielefeld Academic Search Engine
Hepatitis C virus (HCV) infects 3% of the world's population. Treatment of chronic HCV consists of a combination of PEGylated interferon-alpha (PEG-IFN-alpha) and ribavirin (RBV). To identify genetic variants associated with HCV treatment response, w
Autor:
Stefan Taube, Justus Welke, V. Weich, Manfred Wiese, Christoph Sarrazin, Hermann E. Wasmuth, Eckart Schreier, Eckart Schott, Frank Lammert, J. Halangk, Golo Ahlenstiel, Ulrich Spengler, Heiko Witt, Uwe Goebel, Thomas Berg, Andreas Mas Marques, B. Schlosser, Tobias Mueller
Publikováno v:
Infection, Genetics and Evolution. 9:847-852
Low-density lipoprotein receptor (LDLR) is involved in the entry of hepatitis C virus (HCV) in host cells. We investigated whether three single-nucleotide alterations within LDLR might be associated with the course of hepatitis C infection and respon
Autor:
Hans Dieter Nischalke, Golo Ahlenstiel, M Biermer, Jacob Nattermann, Thomas Berg, Karin Bueren, Ulrich Spengler, Martin Vogel, Jürgen K. Rockstroh, Frank Grünhage, Tilman Sauerbruch
Publikováno v:
Journal of Hepatology. 47:348-355
Background/Aims Response to HCV treatment with pegylated interferon-α is variable but might at least in part depend on genetic host factors. The G protein β3 unit (GNB3) C825T polymorphism has been shown to affect treatment response in HCV mono-inf